|
Article Excerpt
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has initiated enrollment and patient dosing in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-1504 against methotrexate (MTX) in rheumatoid arthritis (RA) patients.
CH-1504, a non-metabolized antifolate, is engineered to provide the same potent efficacy as MTX but without the side effects caused by the metabolic breakdown of MTX into by-products that are believed to play a significant role in the liver and kidney toxicities and tolerability related side effects associated with chronic therapy. In order to accurately compare the efficacy and tolerability profile and assess the suitability of CH-1504 as a first-line treatment alternative to...
|
|
More articles from Biotech Business
FDA ACCEPTS AZX100 IND FOR DERMAL/HYPERTROPHIC SCARRING.(Clinical repo..., March 01, 2008
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
